# BPA #36E79727A0005

VA Pharmaceutical BPA for Rare-Disease Treatments

**Buyer:** Department of Veterans Affairs

**Award Amount:** $33,094,350.00
**Ceiling:** $33,094,350.00

**Awarded:** October 28, 2026
**Period of Performance:** Oct 28, 2026 - Oct 27, 2027

**Identifier:** 36E79727A0005
**NAICS:** 325412

This is a blanket purchase agreement (BPA) under the Department of Veterans Affairs’ Federal Supply Schedule contract. It enables the VA to order carglumic acid, Cystadane, Signifor, Isturisa, and Cystadrops—prescription medicines used to treat rare or specialized conditions. The supplier, Recordati Rare Diseases, Inc., specializes in pharmaceuticals for rare diseases and related conditions. The agreement supports access to these treatments for veteran healthcare and provides a purchasing arrangement for anticipated needs; the record does not identify specific order quantities or delivery locations. The BPA is associated with the parent FSS contract, which was awarded through full and open competition. Competition details for this BPA itself are not provided. The BPA is scheduled to run from late 2026 through late 2027, with potential performance shown as extending beyond that period. No acquisition program, subcontractors, prior related contracts beyond the parent FSS contract, or original solicitation details are provided.

### Description

BPA FOR CARGLUMIC ACID, CYSTADANE, SIGNIFOR, ISTURSIA, AND CYSTADROPS

[View original record](https://www.usaspending.gov/award/CONT_IDV_36E79727A0005_3600)
